PNOC is proud of the exceptional commitment and work of our sites across the United States, the Australian & New Zealand Children’s Haematology/Oncology Group, Canada, Egypt, Europe, India, Israel, and South America.

About PNOC. Our Core Values are driven by the need to quickly address the significant unmet need of children and young adults with CNS tumors with a set of guiding principles.

In 2019, PNOC established disease specific “working groups” with the main intent to bring clinicians, scientists, philanthropy, and families together to enhance clinical trial development and cultivate the most comprehensive correlative studies for each PNOC trial.

The RAS/RAF/MEK/ERK pathway is implicated in a number of adult cancers and NF1-associated tumors. Similarly, the majority of pediatric LGGs possess abnormal signaling through the RAS/RAF/MEK/ERK pathway as do a variety of other CNS tumor types including high grade glioma, pleomorphic xanthoastrocytoma and ganglioma.

To measure the relative changes in cell cycle-related genetic signature of the tumor microenvironment post administration of neoadjuvant nivolumab in children and young adults with recurrent or progressive HGG when compared to a cohort of archived non-treated recurrent pediatric HGG samples.

ATRT. Atypical teratoid rhabdoid tumor (AT/RT) is a rare, malignant tumor that occurs in the brain and spinal cord of young children. AT/RT can look like many other tumors under the microscope and is diagnosed based on the presence of a mutation in SMARCB1, or rarely SMARCA4.. Unfortunately, despite aggressive multi-modal therapy, children with this disease still have a …

PRIMARY OBJECTIVES. Strata A & B: To determine the safety and recommended phase 2 dose of modified measles virus if administered into the tumor bed of patients with locally recurrent medulloblastoma or ATRT or into the subarachnoid space of patients with disseminated medulloblastoma or ATRT.

Patients 1-25 years of age with a histologically confirmed diagnosis of low grade gliomas (LGGs) (WHO grade I-II) that is progressive after prior treatment or high grade gliomas.. A combination of trametinib and everolimus will be administered in two …

The study will use a new treatment approach based on the molecular characteristics of each participant’s tumor. The study will test the feasibility of performing real-time drug screening on tissue taken during surgery, and of having a specialized tumor board assign a treatment plan based on the results of this screening and genomic sequencing.

Please note, this study has closed to accrual and is no longer accepting patients. Subjects randomized to Arm 1 (~9% of subjects) will not receive tozuleristide but will undergo standard of care neurosurgery and will have imaging performed with the Canvas System.